Guided Therapeutics (GTHP) Non-Current Deferred Tax Liability (2013 - 2014)
Guided Therapeutics' (GTHP) quarterly Non-Current Deferred Tax Liability came in at $26.0 million in Q4 2014, up 14.32% year-over-year from $22.7 million in Q4 2013, and up 14.32% quarter-over-quarter from $22.7 million in Q4 2013.
Powered by 
Analysis
Guided Therapeutics (GTHP) Non-Current Deferred Tax Liability (2013 - 2014) Analysis & Trends
Guided Therapeutics has disclosed Non-Current Deferred Tax Liability across 2 years of filings, most recently posting $26.0 million for Q4 2014.
- In Q4 2014, Non-Current Deferred Tax Liability rose 14.32% year-over-year to $26.0 million; the TTM figure through Dec 2014 stood at $26.0 million (up 14.32% YoY), while the FY2014 annual figure was $26.0 million, up 14.32% from the prior year.
- Non-Current Deferred Tax Liability came in at $26.0 million for Q4 2014 at Guided Therapeutics, up from $22.7 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $26.0 million in Q4 2014 to a low of $22.7 million in Q4 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Guided Therapeutics | 24.13 Mn | 24.12 Mn | - |